REG - Polarean Imaging PLC - Block Listing Six Monthly Return

Polarean ImagingAnnouncement

27/07/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230727:nRSa2883Ha&default-theme=true

RNS Number : 2883H  Polarean Imaging PLC  27 July 2023

Polarean Imaging Plc

("Polarean" or the "Company")

Block Listing Six Monthly Return

 

Polarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in
advanced MRI scanning of the lungs, today makes the following notification
pursuant to Schedule Six of the AIM Rules for Companies regarding its existing
block admission arrangements:

 Name of applicant:                                                                     Polarean Imaging Plc
 Name of scheme:                                                                        Polarean Share Option Plan
 Number and class of securities originally admitted:                                    8,000,000 ordinary shares of £0.00037 each
 Date of admission:                                                                     29 July 2021
 Period of return:                                         From:                        26 January 2023  To:              26 July 2023
 Balance of unallotted securities under scheme(s) from previous return:                 4,025,657
 Plus: The amount by which the block scheme(s) has been increased since the             0
 date of the last return (if any increase has been applied for):
 Less: Number of securities issued/allotted under scheme(s) during period (see          852,822
 LR3.5.7G):

 Equals: Balance under scheme(s) not yet issued/allotted at end of period:              3,172,835
 Total number of securities in issue at the end of the period                           213,900,331

 Name of contact:              Charles F. Osborne, Jr., Chief Financial Officer
 Telephone number of contact:  + 44 (0)20 7933 8780 or polarean@walbrookpr.com
                               (mailto:polarean@walbrookpr.com)

 

 

Enquiries:

 

 Polarean Imaging plc                                     www.polarean.com (http://www.polarean.com) / www.polarean-ir.com
                                                          (http://www.polarean-ir.com)
 Christopher von Jako, Chief Executive Officer            Via Walbrook PR
 Kenneth West, Chairman

 Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)                 +44 (0)20 7710 7600
 Nicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare Investment
 Banking)
 Nick Adams / Nick Harland (Corporate Broking)

 Walbrook PR        Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
                    (mailto:polarean@walbrookpr.com)
 Anna Dunphy / Phillip Marriage        Mob: +44 (0)7876 741 001 / +44 (0) 7867 984 082

 

About Polarean (www.polarean.com (http://www.polarean.com) )

The Company and its wholly owned subsidiary, Polarean, Inc. (together the
"Group") are revenue-generating, medical imaging technology companies
operating in the high-resolution medical imaging space. Polarean aspires to
revolutionise pulmonary medicine by bringing the power and safety of MRI to
the respiratory healthcare community in need of new solutions to evaluate lung
ventilation, diagnose disease, characterise disease progression, and monitor
response to treatment. By researching, developing, and commercialising novel
imaging solutions with a non-invasive and radiation-free functional imaging
platform. Polarean's vision is to help address the global unmet medical needs
of more than 500 million patients worldwide suffering with chronic respiratory
disease. Polarean is a leader in the field of hyperpolarisation science and
has successfully developed the first and only hyperpolarised MRI contrast
agent to be approved in the United States.   The company also commercialises
systems (such as the HPX hyperpolarisation system), accessories (such as
Xe-specific chest coils and phantoms) and FDA-cleared post-processing software
(to support ventilation defect analysis), to support fully integrated modern
respiratory imaging operations.

 

 

PLC-RNS-2314

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLRNKABBDBKDKOB